Results 91 to 100 of about 3,536 (218)

Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience.

open access: yes, 2014
Plasma exchange (PEX) is a life-saving therapeutic procedure in patients with thrombotic thrombocytopaenic purpura (TTP) and other thrombotic microangiopathic anaemias (TMAs). However, it may be associated with significant complications, exacerbating the
McGuckin, S   +5 more
core  

Glomerular plasmalemma vesicle‐associated protein‐1 as an endothelial remodelling marker complementing C4d in chronic active antibody‐mediated rejection

open access: yesHistopathology, EarlyView.
Glomerular plasmalemma vesicle‐associated protein‐1 (PV‐1/PLVAP) identifies dynamic endothelial remodelling in chronic active antibody‐mediated rejection (caABMR), complementing glomerular C4d, which reflects a static footprint of complement activation. Combined assessment of PV‐1 and C4d captures complementary dimensions of microvascular pathology and
Yuto Igarashi   +7 more
wiley   +1 more source

Acute Kidney Injury in Pregnancy: The Changing Landscape for the 21st Century

open access: yesKidney International Reports, 2018
Pregnancy-related acute kidney injury (Pr-AKI) remains a large public health problem, with decreasing incidences in developing countries but seemingly increasing incidences in the United States and Canada.
Swati Rao, Belinda Jim
doaj   +1 more source

Exercise‐induced vasculitis with histological and genetic evidence of complement involvement

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Massimo Cugno   +6 more
wiley   +1 more source

Beyond the Kidney and Lung: Cutaneous and Mucosal Clues to Human Hantavirus Disease

open access: yesInternational Journal of Dermatology, EarlyView.
Rodent exposure and aerosolized excreta can lead to hantavirus infection with systemic endothelial injury and capillary leak, resulting in thrombocytopenia and syndromes such as HPS/HCPS and HFRS/NE. Early dermatologic and mucosal findings, including flushing, conjunctival injection, petechiae/purpura, and mucosal bleeding, may provide important clues ...
Giuseppe Gallo   +2 more
wiley   +1 more source

Feasibility and outcomes of kidney transplantation in patients with end‐stage kidney disease after haemopoietic stem cell transplantation

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Advances in haemopoietic stem cell transplantation (HSCT) have improved long‐term survival, but they have also led to late complications, such as nephropathy. However, the safety and feasibility of kidney transplantation (KT) in patients with HSCT‐related end‐stage kidney disease (ESKD) remain unclear.
Bioh Kim   +6 more
wiley   +1 more source

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral‐treated human immunodeficiency virus infection

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background and Aims Antiretroviral therapy (ART) has modified the incidence of renal complications and the patterns of renal disease in people living with Human Immunodeficiency Virus (PLWH). We reviewed (2011–2021) the progress and outcomes (follow‐up to mid‐2025) of 158 such individuals.
Jacqueline A. Evans   +5 more
wiley   +1 more source

ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies

open access: yesRambam Maimonides Medical Journal, 2014
Thrombotic microangiopathies (TMAs) comprise a group of distinct disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis.
Galit Sarig
doaj   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy